Notably, research has shown that B-ALL patients with CD10-positive expression tend to have a favorable prognosis [41], suggesting that individuals with common B-ALL might have better outcomes than those with pro-B-ALL; as expected, BCR/TCR diversity was greater in common B-ALL patients than in pro-B-ALL patients, suggesting a better prognosis with higher BCR/TCR diversity and lower clonal abundance. This evidence concerns the gene MME and precursor B-cell acute lymphoblastic leukemia.